Valuation : Imunon, Inc.

Market Cap 9.15M 7.85M 7.35M 6.73M 12.68M 874M 12.72M 87.04M 34.03M 440M 34.34M 33.6M 1.46B P/E 2026 *
-0.68x
P/E 2027 * -0.88x
Enterprise Value 9.15M 7.85M 7.35M 6.73M 12.68M 874M 12.72M 87.04M 34.03M 440M 34.34M 33.6M 1.46B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.86%
Yield 2026 *
-
Yield 2027 * -
1 day-1.84%
1 week+1.27%
Current month+0.63%
1 month+5.96%
3 months-27.27%
6 months-49.37%
Current year-58.01%
1 week 1.55
Extreme 1.55
1.7
1 month 1.47
Extreme 1.47
1.72
Current year 1.47
Extreme 1.47
4.2
1 year 1.47
Extreme 1.47
6.35
3 years 1.47
Extreme 1.47
47.61
5 years 1.47
Extreme 1.47
219.13
10 years 1.47
Extreme 1.47
3,780.03
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Date Insider Type Main position Quantity % Market Cap.
8/17/26 A Sell

General Counsel

-2,449 0.0971%
8/14/26 A Free

Chief Technology Officer

3,516 0.1395%
8/14/26 A Free

Chief Executive Officer

6,615 0.2624%
Change 5-day change 1-year change 3-year change Capi.($)
-1.84%+1.27%-74.36%-89.86% 9.15M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+3.40%+51.59%+93.39% 65.4B
-1.03%-1.52%+6.31%-5.28% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-2.41%-7.09%-8.16%+455.82% 27.16B
+0.37%+0.70%+37.37%-15.78% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.50%+1.60%+44.13%+151.30% 13.9B
Average +0.18%+1.36%+45.02%+164.78% 28.83B
Weighted average by Cap. +0.99%+0.72%+55.94%+155.09%

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.42M -11.63M -10.65M -20.06M -1.38B -20.11M -138M -53.82M -696M -54.32M -53.14M -2.3B -19.34M -16.61M -15.55M -14.24M -26.82M -1.85B -26.89M -184M -71.96M -931M -72.63M -71.06M -3.08B
Net Debt - -
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
27/08/26 $1.600 -1.84% 21,729
26/08/26 $1.630 -1.81% 48,408
25/08/26 $1.660 +4.40% 86,616
24/08/26 $1.590 -3.05% 33,053
21/08/26 $1.640 +3.80% 58,859
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.600USD
Average target price
17.00USD
Spread / Average Target
+962.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMNN Stock